SUNY Upstate Medical University

State University of New York

Syracuse, NY

Sorting 2 by

Accepting patients

MonumenTAL-6

A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
  • Bispecific Antibody
  • CD3
  • GPRC5D
  • Randomization
  • Phase 3

Accepting patients

EQUATE

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
  • Monoclonal Antibody
  • CD38
  • Phase 3